Compare ALLO & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | NPCE |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.4M | 432.3M |
| IPO Year | 2018 | 2021 |
| Metric | ALLO | NPCE |
|---|---|---|
| Price | $2.32 | $16.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $8.35 | ★ $18.33 |
| AVG Volume (30 Days) | ★ 14.4M | 147.5K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | 29.03 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $99,986,000.00 |
| Revenue This Year | N/A | $0.90 |
| Revenue Next Year | $142,416.42 | $24.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $0.86 | $7.56 |
| 52 Week High | $4.46 | $18.97 |
| Indicator | ALLO | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 70.21 |
| Support Level | $1.92 | $15.25 |
| Resistance Level | $2.71 | $16.96 |
| Average True Range (ATR) | 0.35 | 0.65 |
| MACD | -0.04 | 0.24 |
| Stochastic Oscillator | 17.82 | 75.60 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.